Technology ID
TAB-4887
Cell Lines and Plasmids Expressing Chemokine Receptors in the Development of Therapeutics for Inflammatory Diseases
E-Numbers
E-073-2019-0
Lead Inventor
Murphy, Philip
Lead IC
NIAID
Co-Inventors
Gao, Ji-Liang
Pontejo, Jesus
ICs
NIAID
Applications
Therapeutics
Therapeutic Areas
Immunology
Development Stages
Prototype
Research Products
Plasmids/Vectors
Human Cell Lines
The technology involves the use of specialized cell lines, including HEK 293 cells expressing human CCR1 and CCR2, along with plasmids encoding mouse CCR1 (Ccr1) and CCR2B (Ccr2), as well as their corresponding human receptor sequences. These tools serve as crucial components in the study of chemokine receptors' functions, particularly in the context of inflammatory diseases. By manipulating and analyzing these receptors, researchers can gain insights into their roles in cellular responses related to inflammation. Furthermore, this technology provides a foundation for drug development efforts aimed at modulating these receptors to develop innovative therapeutics for various inflammatory conditions.
Commercial Applications
This technology finds applications in studying and potentially treating a variety of inflammatory diseases, including arthritis, asthma, and autoimmune disorders. It also has the potential to advance vaccine development, immunotherapy research, and drug screening for inflammatory conditions, making it a versatile tool with broad biomedical applications.
Competitive Advantages
This technology provides a competitive edge in inflammatory disease drug development. The specialized cell lines offer reliable models for studying receptor functions, while versatile plasmids enable tailored experiments. This flexibility accelerates research and facilitates the development of targeted therapies for inflammatory conditions, making it a valuable asset in advancing healthcare solutions.
Licensing Contact: